+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID02275286

Phase I-II Study of Trabectedin Combined With Radiotherapy to Treat Soft Tissue Sarcoma Including Liposarcoma and Leiomyosarcoma

Led by Grupo Espanol de Investigacion en Sarcomas · Updated on 2023-05-31

199

Participants Needed

17

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the combination of trabectedin and radiotherapy to reduce tumors in patients with various types of soft tissue sarcoma. This Phase I-II trial evaluates different doses of trabectedin alongside specified radiation doses to measure tumor shrinkage and survival outcomes. The study includes four patient groups based on sarcoma type and tumor location, with cohorts A and B closed to new participants since 2023. The treatment involves intravenous trabectedin given over 24 hours every three weeks at doses of 1.3 or 1.5 mgm2, combined with radiotherapy delivered in fractions ranging from 30 Gy to 45 Gy depending on the patient cohort. Cohort A patients may receive unlimited chemotherapy cycles, while cohorts B and C receive three cycles. Radiotherapy schedules vary by group, and a translational substudy examines biomarkers to predict treatment response. Participants undergo regular tumor imaging with CT and MRI scans, clinical evaluations, and quality of life questionnaires over months to years. Tumor responses are assessed every 6 weeks or 4 months depending on cohort, and safety is monitored through adverse event tracking every 21 days. Survival and relapse outcomes are followed for up to five years. Centralized pathology and radiology reviews support treatment decisions, and all participants must have a central venous catheter for chemotherapy delivery.

CONDITIONS

Brief Title

Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients

Research Team

A

Adriana Rojo

E

Elisa Cerezo, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here